Navigation Menu

Clinical Trial External Search

Children (age < 18 years)
Adults (age >= 18 years)

Researcher Profile

Researcher Display

Joseph Drabick, MD

Joseph Drabick, MD

Professor and Rose Dunlap Division Chief Chair in Hematology/Oncology, Department of Medicine
Division of Hematology and Oncology
Scientific Program:Next-Generation Therapies
Disease Teams:
Cancer Institute, Brain and Central Nervous System Cancer Team
Cancer Institute, Genitourinary Cancer Team
Cancer Institute, Immunotherapy Team
Cancer Institute, Melanoma and Skin Cancer Team
Cancer Institute, Sarcoma Cancer Team

Research Interests

  • Therapeutics
  • Neoplasms
  • Melanoma
  • Survival
  • Drug Therapy
  • Haiti
  • United Nations
  • Vaccines
  • Infections
  • Immunotherapy
  • Skin
  • Radiotherapy

Clinical Trials

General Protocol for the Acquisition of Whole Blood for the Detection and Characterization of Circulating Tumor Cells and/or Tumor Specific Immunity/Immune Cell Activation for any Malignancy at any Stage of Disease
A Retrospective Evaluation to Understand how â-adrenergic Antagonism Impacts the Progression of Melanoma and the Efficacy of Standard Treatments Intended to Eliminate the Cancer
A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab versus Placebo after Surgery and Radiation Therapy in Patients with High Risk Cutaneous Squamous Cell Carcinoma (CSCC)
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US) (NRG-GI008)
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination With Immuno-Oncology Agents in Subjects With Unresectable Advanced or Metastatic Solid Tumors
KEYSTROKE: A Randomized Phase II Study of Pembrolizumab (KEYTRUDA®) Plus Stereotactic Re-irradiation Versus SBRT Alone for Locoregionally Recurrent or Second Primary Head and Neck Carcinoma
APG-115 - A Phase Ib/II Study of APG-115 in Combination with Pembrolizumab in Patients with Unresectable or Metastatic Melanomas or Advanced Solid Tumors
An Open-Label, Randomized, Controlled Multi-Center Study of The Efficacy of Daromun (L19IL2 + L19TNF) Neoadjuvant Intratumoral Treatment Followed by Surgery and Adjuvant Therapy Versus Surgery and Adjuvant Therapy in Clinical Stage IIIB/C Melanoma Patients (PSCI 21-190) (PH-L19IL2TNF-01/18)
A Phase Ib/11 Study of Propranolol with fixed-dose Pembrolizumab in Patients with Unresectable Stage III and Stage IV Melanoma
A Phase II/III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA

Recent Publications


Hiller, A, Oxford, M, Kulkarni, P, Fornadley, J, Lo, A, Sivik, J, Drabick, J & Vakharia, K 2024, 'Efficacy of Cemiplimab as Adjuvant or Neoadjuvant Therapy in the Treatment of Cutaneous Squamous Cell Carcinoma', Annals of plastic surgery, vol. 92, no. 4, pp. S129-S131.


Joshi, M, Tuanquin, L, Zhu, J, Walter, V, Schell, T, Kaag, M, Kilari, D, Liao, J, Holder, SL, Emamekhoo, H, Sankin, A, Merrill, S, Zheng, H, Warrick, J, Hauke, R, Gartrel, B, Stein, M, Drabick, J, Degraff, DJ & Zakharia, Y 2023, 'Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: Results from phase II study, BTCRC-GU15-023', Journal for ImmunoTherapy of Cancer, vol. 11, no. 2, e006551.
Lü, J, Jiang, C, Joshi, M & Drabick, JJ 2023, Giant Angelica: Angelica gigas Nakai – Herbal Giant’s Anticancer Potential. in Ancient and Traditional Foods, Plants, Herbs and Spices used in Cancer. CRC Press, pp. 165-180.


Joshi, M, Holder, SL, Zhu, J, Zheng, H, Komanduri, S, Warrick, J, Yasin, H, Gajre, R, Jia, B, Drabick, JJ, DeGraff, DJ & Zakharia, Y 2022, 'Avelumab in Combination with Eribulin Mesylate in Metastatic Urothelial Carcinoma: BTCRC GU-051, a Phase 1b Study', European Urology Focus, vol. 8, no. 2, pp. 483-490.
Spengler, M, Wheelden, M, MacKley, HB & Drabick, JJ 2021, 'Durable major response with pazopanib in recurrent, heavily pretreated metastatic esthesioneuroblastoma harboring a fumarate hydratase mutation', JCO Precision Oncology, vol. 5, pp. 664-669.
Nesterova, D, Zhu, J, Kramer, C, Vasekar, M, Truica, C, Joshi, A, Hayes, M, Kessler, J, Saunders, EFH, Drabick, JJ & Joshi, M 2022, 'Group-led creative writing and behavioural health in cancer: A randomised clinical trial', BMJ Supportive and Palliative Care, vol. 12, no. 1, pp. 91-98.
Abraham, J, Heimberger, AB, Marshall, J, Heath, E, Drabick, J, Helmstetter, A, Xiu, J, Magee, D, Stafford, P, Nabhan, C, Antani, S, Johnston, C, Oberley, M, Korn, WM & Spetzler, D 2021, 'Machine learning analysis using 77,044 genomic and transcriptomic profiles to accurately predict tumor type', Translational Oncology, vol. 14, no. 3, 101016.
Zaorsky, NG, Khunsriraksakul, C, Acri, SL, Liu, DJ, Ba, DM, Lin, JL, Liu, G, Segel, JE, Drabick, JJ, Mackley, HB & Leslie, DL 2021, 'Medical Service Use and Charges for Cancer Care in 2018 for Privately Insured Patients Younger Than 65 Years in the US', JAMA network open, vol. 4, no. 10, 27784.
Najjar, YG, McCurry, D, Lin, H, Lin, Y, Zang, Y, Davar, D, Karunamurthy, A, Drabick, JJ, Neves, RI, Butterfield, LH, Ernstoff, MS, Puzanov, I, Skitzki, JJ, Bordeaux, J, Summit, ISB, Bender, JO, Kim, JY, Chen, B, Sarikonda, G, Pahuja, A, Tsau, J, Alfonso, Z, Laing, C, Pingpank, JF, Holtzman, MP, Sander, C, Rose, A, Zarour, HM, Kirkwood, JM & Tarhini, AA 2021, 'Neoadjuvant pembrolizumab and high-dose IFNa-2b in resectable regionally advanced melanoma', Clinical Cancer Research, vol. 27, no. 15, pp. 4195-4204.
Gandhi, S, Pandey, MR, Attwood, K, Ji, W, Witkiewicz, AK, Knudsen, ES, Allen, C, Tario, JD, Wallace, PK, Cedeno, CD, Levis, M, Stack, S, Funchain, P, Drabick, JJ, Bucsek, MJ, Puzanov, I, Mohammadpour, H, Repasky, EA & Ernstoff, MS 2021, 'Phase I clinical trial of combination propranolol and pembrolizumab in locally advanced and metastatic melanoma: safety, tolerability, and preliminary evidence of antitumor activity', Clinical Cancer Research, vol. 27, no. 1, pp. 87-95.
Zakharia, Y, McWilliams, RR, Rixe, O, Drabick, J, Shaheen, MF, Grossmann, KF, Kolhe, R, Pacholczyk, R, Sadek, R, Tennant, LL, Smith, CM, Kennedy, EP, Link, CJ, Vahanian, NN, Yu, J, Shen, SS, Brincks, EL, Rossi, GR, Munn, D & Milhem, M 2021, 'Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma', Journal for ImmunoTherapy of Cancer, vol. 9, no. 6, e002057.
Tchelebi, LT, Batchelder, E, Wang, M, Lehrer, EJ, Drabick, JJ, Sharma, N, MacHtay, M, Trifiletti, DM & Zaorsky, NG 2021, 'Radiotherapy and Receptor Tyrosine Kinase Inhibition for Solid Cancers (ROCKIT): A Meta-Analysis of 13 Studies', JNCI Cancer Spectrum, vol. 5, no. 4, pkab050.


Zheng, H, Mineishi, S, Claxton, D, Zhu, J, Zhao, C, Jia, B, Ehmann, WC, Rybka, WB, Naik, S, Songdej, N, Drabick, JJ & Hohl, RJ 2021, 'A phase I clinical trial of avelumab in combination with decitabine as first line treatment of unfit patients with acute myeloid leukemia', American Journal of Hematology, vol. 96, no. 2, pp. E46-E50.
Joshi, M, Grivas, P, Mortazavi, A, Monk, P, Clinton, SK, Sue-Ann Woo, M, Holder, SL, Drabick, JJ & Yin, M 2020, 'Alterations of DNA damage response genes correlate with response and overall survival in anti-PD-1/PD-L1-treated advanced urothelial cancer', Cancer medicine, vol. 9, no. 24, pp. 9365-9372.
Rao, P, Segel, JE, McGregor, LM, Lengerich, EJ, Drabick, JJ & Miller, B 2020, 'Attendance at National Cancer Institute and Children's Oncology Group Facilities for Children, Adolescents, and Young Adults with Cancer in Pennsylvania: A Population-Based Study', Journal of Adolescent and Young Adult Oncology, vol. 9, no. 1, pp. 47-54.
Pancholy, N, Walter, V, Drabick, J, Fox, EJ, Zaorsky, N & Vasekar, M 2020, 'Growth factor and its role in the treatment of patients with soft tissue extremity sarcoma receiving chemotherapy managed at an academic center: A retrospective study', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 38, no. 15_suppl, e23573.
Moku, P, Shepherd, L, Ali, SM, Leitzel, K, Parulekar, WR, Zhu, L, Virk, S, Nomikos, D, Aparicio, S, Gelmon, K, Drabick, J, Cream, L, Halstead, ES, Umstead, TM, Mckeone, D, Polimera, H, Maddukuri, A, Ali, A, Nagabhairu, V, Poulose, J, Pancholy, N, Spiegel, H, Chen, BE & Lipton, A 2020, 'Higher serum PD-L1 level predicts increased overall survival with lapatinib versus trastuzumab in the CCTG MA.31 phase 3 trial', Cancer, vol. 126, no. 22, pp. 4859-4866.
Liu, J, Xu, C, Zhu, J, Sivik, J, Drabick, JJ & Mackley, HB 2020, 'Identifying the optimal fractionation schedules for improved response rates and survival in patients with metastatic melanoma treated with ipilimumab and radiotherapy', Current Cancer Therapy Reviews, vol. 16, no. 1, pp. 78-85.
Najjar, YG, Navrazhina, K, Ding, F, Bhatia, R, Tsai, K, Abbate, K, Durden, B, Eroglu, Z, Bhatia, S, Park, S, Chowdhary, A, Chandra, S, Kennedy, J, Puzanov, I, Ernstoff, M, Vachhani, P, Drabick, J, Singh, A, Xu, T, Yang, J, Carvajal, R, Manson, D, Kirkwood, JM, Cohen, J, Sullivan, R, Johnson, D, Funchain, P & Shoushtari, A 2020, 'Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study', Journal for ImmunoTherapy of Cancer, vol. 8, no. 1.
Hendriksen, BS, Stahl, KA, Hollenbeak, CS, Taylor, MD, Vasekar, MK, Drabick, JJ, Conte, JV, Soleimani, B & Reed, MF 2021, 'Postoperative chemotherapy and radiation improve survival following cardiac sarcoma resection', Journal of Thoracic and Cardiovascular Surgery, vol. 161, no. 1, pp. 110-119.e4.
Yin, M, Grivas, P, Wang, QE, Mortazavi, A, Emamekhoo, H, Holder, SL, Drabick, JJ, Woo, MSA, Pal, S, Vasekar, M, Folefac, E, Clinton, SK, Monk, P & Joshi, M 2020, 'Prognostic Value of DNA Damage Response Genomic Alterations in Relapsed/Advanced Urothelial Cancer', Oncologist, vol. 25, no. 8, pp. 680-688.
Schmitz, KH, Potiaumpai, M, Schleicher, EA, Wolf, LJ, Doerksen, SE, Drabick, JJ, Yee, NS, Truica, CI, Mohamed, AA, Shaw, BW & Farley, DC 2021, 'The exercise in all chemotherapy trial', Cancer, vol. 127, no. 9, pp. 1507-1516.
Sha, CM, Lehrer, EJ, Hwang, C, Trifiletti, DM, Mackley, HB, Drabick, JJ & Zaorsky, NG 2020, 'Toxicity in combination immune checkpoint inhibitor and radiation therapy: A systematic review and meta-analysis', Radiotherapy and Oncology, vol. 151, pp. 141-148.